当前位置： SCI文献检索 > ALIMENTARY PHARMACOLOGY & THERAPEUTICS期刊下所有文献 > Meta-analysis: Lactobacillus GG for treating acute diarrhoea in children.

Meta-analysis: Lactobacillus GG for treating acute diarrhoea in children.

Abstract：

AIM:To review evidence for the effectiveness of Lactobacillus GG (LGG) in treating acute infectious diarrhoea in children. METHODS:The following electronic databases were searched through August 2006 for studies relevant to acute infectious diarrhoea and LGG: MEDLINE, EMBASE, CINAHL and The Cochrane Library; additional references were obtained from reviewed articles. Only randomized-controlled trials (RCTs) were included. RESULTS:Eight RCTs (988 participants) met the inclusion criteria. Compared with controls, LGG had no effect on the total stool volume (two RCTs, n = 303). However, LGG was associated with a significant reduction in diarrhoea duration (seven RCTs, 876 infants, weighted mean difference, WMD -1.1 days (95% confidence interval, CI -1.9 to -0.3), particularly of rotavirus etiology (WMD -2.1 days, 95% CI -3.6 to -0.6), risk of diarrhoea >7 days (one RCT, n = 287, relative risk 0.25, 95% CI 0.09-0.75) and duration of hospitalization (three RCTs, n = 535, WMD -0.58, 95% CI -0.8 to -0.4; significance was lost in the random effect model). There was no reduction in the number of stools at any time interval. CONCLUSIONS:The use of LGG is associated with moderate clinical benefits in the treatment of acute diarrhoea in children. These findings should be interpreted with caution due to the important methodological limitations and heterogeneity of most of the studies.

journal_name

Aliment Pharmacol Ther

journal_title

Alimentary pharmacology & therapeutics

authors

Szajewska H,Skórka A,Ruszczyński M,Gieruszczak-Białek D

doi

10.1111/j.1365-2036.2007.03282.x

subject

Has Abstract

pub_date

2007-04-15 00:00:00

pages

871-81

issue

8

eissn

0269-2813

issn

1365-2036

pii

APT3282

journal_volume

25

pub_type

杂志文章,meta分析,评审

相关文献

ALIMENTARY PHARMACOLOGY & THERAPEUTICS文献大全
  • A non-toxic analogue of a coeliac-activating gliadin peptide: a basis for immunomodulation?

    abstract：BACKGROUND:A-gliadin residues 31-49 (peptide A) binds to HLA-DQ2 and is toxic to coeliac small bowel. Analogues of this peptide, which bind to DQ2 molecules but are non-toxic, may be a potential route to inducing tolerance to gliadin in patients with coeliac disease. METHODS:Toxicity was investigated with small bowel ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1046/j.1365-2036.1999.00512.x

    authors： Biagi F,Ellis HJ,Parnell ND,Shidrawi RG,Thomas PD,O'Reilly N,Corazza GR,Ciclitira PJ

    更新日期：1999-07-01 00:00:00

  • Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study.

    abstract：BACKGROUND:Delta virus (HDV)-related chronic hepatitis is difficult to treat. AIMS:To evaluate the efficacy of lamivudine 100 mg daily on serum HDV-RNA, hepatitis D virus antibodies and alanine aminotransferase levels, liver histology, and on hepatitis B surface antigen seroconversion. METHODS:Thirty-one hepatitis B ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1111/j.1365-2036.2005.02542.x

    authors： Niro GA,Ciancio A,Tillman HL,Lagget M,Olivero A,Perri F,Fontana R,Little N,Campbell F,Smedile A,Manns MP,Andriulli A,Rizzetto M

    更新日期：2005-08-01 00:00:00

  • Symptomatic improvement with one-year cisapride treatment in neuropathic chronic intestinal dysmotility.

    abstract：AIM:To assess the efficacy of a prokinetic agent in the long-term treatment of chronic intestinal dysmotility and the influence of extrinsic denervation. METHODS:We assessed symptoms, compliance and untoward effects in an open, 1-year trial of cisapride, 20 mg t.d.s., in 37 patients with neuropathic forms of chronic i...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1111/j.0953-0673.1996.00403.x

    authors： Camilleri M,Balm RK,Zinsmeister AR

    更新日期：1996-06-01 00:00:00

  • The use of adalimumab in the management of refractory Crohn's disease.

    abstract：BACKGROUND:Adalimumab is a humanized monoclonal antibody targeting tumour necrosis factor-alpha. Recent clinical trials have demonstrated its efficacy in Crohn's disease; however, experience in clinical practice remains limited. AIM:To investigate the efficacy and safety of adalimumab in the clinical setting. METHODS...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章

    doi：10.1111/j.1365-2036.2007.03583.x

    authors： Ho GT,Smith L,Aitken S,Lee HM,Ting T,Fennell J,Lees CW,Palmer KR,Penman ID,Shand AG,Arnott ID,Satsangi J

    更新日期：2008-02-15 00:00:00

  • The effect of trospium chloride on oesophageal motility.

    abstract：:Trospium chloride is a muscarinergic antagonist acting on oesophageal smooth muscle and on ganglionic and/or myenteric neurons. The effect of this drug on oesophageal motility was tested in 16 healthy male subjects in a double-blind randomized cross-over examination of trospium chloride or placebo following phentolami...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1111/j.1365-2036.1993.tb00072.x

    authors： Frieling T,Enck P,Dohmann R,Wienbeck M,Lübke HJ

    更新日期：1993-02-01 00:00:00

  • Proton pump inhibitors: better acid suppression when taken before a meal than without a meal.

    abstract：BACKGROUND:Proton pump inhibitors including omeprazole and lansoprazole inhibit gastric acid secretion by selectively and non-competitively inactivating the H+, K+ ATPase molecules of the parietal cell, but possibly only those that are actively secreting acid. This might imply that stimulation of acid secretion by a me...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1046/j.1365-2036.2000.00829.x

    authors： Hatlebakk JG,Katz PO,Camacho-Lobato L,Castell DO

    更新日期：2000-10-01 00:00:00

  • Novel score for prediction of malignant bile duct obstruction based on biochemical and clinical markers.

    abstract：BACKGROUND:Early differentiation of malignant from benign bile duct obstruction is of utmost importance. AIM:To identify biochemical and clinical predictors for malignancy in patients with bile duct obstruction, and establish a predictive model by combining pre-treatment patient characteristics. A web-based applicatio...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.13152

    authors： Meister T,Uphoff MA,Heinecke A,Domagk D,Kunsch S,Lindhorst A,Ellenrieder V,Heinzow HS

    更新日期：2015-05-01 00:00:00

  • Review article: prognosis of hepatorenal syndrome--has it changed with current practice?

    abstract：:The Consensus Conference on Hepatorenal Syndrome (HRS) organized by the International Ascites Club in 1994 redefined HRS, introduced new diagnostic criteria that are now widely accepted, and proposed the distinction between two types of HRS: type 1 and type 2. Before the introduction of the new therapeutic options, th...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2036.2004.02113.x

    authors： Angeli P

    更新日期：2004-09-01 00:00:00

  • Helicobacter pylori eradication and peptic ulcer healing: the impact of deleting the proton pump inhibitor and using a once-daily treatment.

    abstract：AIM:To compare cheaper and simpler once-daily regimens, with and without a proton pump inhibitor, with standard, twice-daily, triple therapy. METHODS:A randomized, placebo-controlled, treatment trial in Vietnam allocated 296 Helicobacter pylori-infected patients with peptic ulcer of >or= 5 mm to one of three regimens:...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1046/j.1365-2036.2003.01649.x

    authors： Wheeldon TU,Hoang TT,Phung DC,Björkman A,Granström M,Sörberg M

    更新日期：2003-07-01 00:00:00

  • Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study.

    abstract：BACKGROUND:Faecal calprotectin is a reliable tool for predicting Crohn's disease (CD) relapse in patients with sustained remission. Prediction of relapse with faecal calprotectin has been less studied in patients with severe CD treated with anti-TNF. AIM:To identify an association between faecal calprotectin concentra...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2011.04743.x

    authors： Laharie D,Mesli S,El Hajbi F,Chabrun E,Chanteloup E,Capdepont M,Razaire S,de Lédinghen V,Zerbib F

    更新日期：2011-08-01 00:00:00

  • A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Multicentre Investigational Group.

    abstract：BACKGROUND:Lansoprazole is a new proton pump inhibitor which produces prolonged decrease of gastric acidity. The aim of this study was to compare lansoprazole to a standard dose of ranitidine in the treatment of patients with reflux oesophagitis. METHODS:Two hundred and forty-seven patients with erosive oesophagitis w...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1111/j.1365-2036.1995.tb00347.x

    authors： Robinson M,Sahba B,Avner D,Jhala N,Greski-Rose PA,Jennings DE

    更新日期：1995-02-01 00:00:00

  • Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man.

    abstract：:The bioavailability of three pure 5-aminosalicylic (5-ASA) preparations (Asacol, Claversal, and Pentasa) was studied in 8 ileostomy patients and 12 normal subjects after 6 days of treatment with 2000 mg 5-ASA. The local bioavailability, reflected by the 5-ASA concentration was thereby measured at two clinically releva...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.1990.tb00499.x

    authors： Christensen LA,Fallingborg J,Abildgaard K,Jacobsen BA,Sanchez G,Hansen SH,Bondesen S,Hvidberg EF,Rasmussen SN

    更新日期：1990-10-01 00:00:00

  • Twenty-four-hour intragastric acidity in duodenal ulcer patients during dosing with placebo, and 150 mg ranitidine twice or four times daily.

    abstract：:Twenty-four-hour intragastric acidity was measured in 10 patients with a past history of duodenal ulcer on the fourth day of dosing with placebo, and either 150 mg ranitidine given twice or four times daily. The order of the treatments was randomized and a double-blind design was employed. Ranitidine (150 mg) b.d. dec...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1111/j.1365-2036.1989.tb00211.x

    authors： Howden CW,Tsai HH,Reid JL

    更新日期：1989-06-01 00:00:00

  • Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial.

    abstract：BACKGROUND:The role of mesalazine in preventing the clinical recurrence of Crohn's disease after surgery has been shown in a meta-analysis of all published studies. No clear relationship, however, has been shown between dosage and response. AIM:To evaluate whether 4.0 g/day of mesalazine may offer therapeutic advantag...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1046/j.1365-2036.2003.01462.x

    authors： Caprilli R,Cottone M,Tonelli F,Sturniolo G,Castiglione F,Annese V,Papi C,Viscido A,Cammà C,Corrao G,Latella G

    更新日期：2003-02-15 00:00:00

  • Natural course of treated and untreated chronic HCV infection: results of the nationwide Hepnet.Greece cohort study.

    abstract：BACKGROUND:Interferon (IFN-alpha)-based regimens have been used with varying success in the treatment of chronic hepatitis C (CHC) for over two decades. The effect of such treatments on the natural course of CHC has been evaluated in small clinical trials with conflicting results. AIM:To investigate the natural course...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究

    doi：10.1111/j.1365-2036.2009.03974.x

    authors： Manesis EK,Papatheodoridis GV,Touloumi G,Karafoulidou A,Ketikoglou J,Kitis GE,Antoniou A,Kanatakis S,Koutsounas SJ,Vafiadis I,HEPNET.Greece Cohort Study.

    更新日期：2009-05-15 00:00:00

  • Clinical trial: percutaneous acetic acid injection vs. percutaneous ethanol injection for small hepatocellular carcinoma--a long-term follow-up study.

    abstract：BACKGROUND:The long-term outcome of percutaneous acetic acid injection (PAI) and percutaneous ethanol injection (PEI) for treating small hepatocellular carcinoma (HCC) remains unclear. AIM:To compare the long-term outcome of PAI vs. PEI for treating small HCC. METHODS:From July 1998 to July 2004, 125 patients with sm...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2008.03702.x

    authors： Tsai WL,Cheng JS,Lai KH,Lin CP,Lo GH,Hsu PI,Yu HC,Lin CK,Chan HH,Chen WC,Chen TA,Li WL,Liang HL

    更新日期：2008-08-01 00:00:00

  • Personal view: adequate relief as a primary endpoint in irritable bowel syndrome.

    abstract：:The success of a clinical trial is judged by achieving statistical and clinical significance on the primary endpoint. This is particularly relevant in those trials that are initiated to achieve regulatory approval of a new therapeutic agent. Selection of an endpoint for which statistical significance will be too diffi...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2036.2006.02839.x

    authors： Mangel AW

    更新日期：2006-04-01 00:00:00

  • Review article: potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease.

    abstract：:Unfractioned heparin was recently reported to be beneficial in the treatment of inflammatory bowel disease. The available uncontrolled data show that it may be effective in steroid-resistant ulcerative colitis with a percentage of complete clinical remission of over 70% after an average of 4-6 weeks of therapy. The ad...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1046/j.1365-2036.2000.00860.x

    authors： Papa A,Danese S,Gasbarrini A,Gasbarrini G

    更新日期：2000-11-01 00:00:00

  • Systematic review: the economic impact of irritable bowel syndrome.

    abstract：BACKGROUND:Although little mortality is associated with irritable bowel syndrome, curative therapy does not exist and thus the economic impact of this disorder may be considerable. METHODS:A systematic review of the literature was performed. Studies were included if their focus was irritable bowel syndrome, and direct...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1046/j.1365-2036.2003.t01-1-01736.x

    authors： Inadomi JM,Fennerty MB,Bjorkman D

    更新日期：2003-10-01 00:00:00

  • Glicentin, an active enteroglucagon, has a significant trophic role on the small intestine but not on the colon in the rat.

    abstract：BACKGROUND:Many experiments have indicated that the gut glucagons (enteroglucagons) are associated with cell proliferation in the small intestine. However, recent studies have failed to show trophic effects of glicentin (enteroglucagon) on the intestine. AIMS:To examine the effects of glicentin on intestinal prolifera...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1046/j.1365-2036.2001.01082.x

    authors： Sasaki M,Fitzgerald AJ,Mandir N,Sasaki K,Wright NA,Goodlad RA

    更新日期：2001-10-01 00:00:00

  • Increased prevalence of autoimmune diseases in functional gastrointestinal disorders: case-control study of 23471 primary care patients.

    abstract：BACKGROUND:There is increasing evidence that impaired mucosal defence mechanisms are implicated in the pathogenesis of the functional gastrointestinal disorders (FGIDs), allowing inappropriate immune activation. AIM:To test the hypothesis that an excess of autoimmune disorders among sufferers, using a large primary ca...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.12903

    authors： Ford AC,Talley NJ,Walker MM,Jones MP

    更新日期：2014-10-01 00:00:00

  • Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study.

    abstract：BACKGROUND:Chronic constipation may result in disabling symptoms, is often unsatisfactorily treated by laxatives and negatively impacts quality of life (QoL). AIM:A randomized, double-blind, placebo-controlled, phase III trial to evaluate the efficacy and safety of a selective, high-affinity 5-HT(4) receptor agonist, ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1111/j.1365-2036.2008.03884.x

    authors： Quigley EM,Vandeplassche L,Kerstens R,Ausma J

    更新日期：2009-02-01 00:00:00

  • Review article: colon-saving medical therapy vs. colectomy in ulcerative colitis - the case for colectomy.

    abstract：:In the era of expanding medical therapy for ulcerative colitis, surgery is still a very valid option in those patients, where medicine is not able to control symptoms, both in the acute and chronic stages, and also for those at risk of developing a cancer. The ileal pouch-anal anastomosis (IPAA) will, for the vast maj...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2036.2006.03065.x

    authors： Oresland T

    更新日期：2006-10-01 00:00:00

  • Review article: the limitations of corticosteroid therapy in Crohn's disease.

    abstract：:Corticosteroids are highly effective in inducing clinical remission in patients with active Crohn's disease. However, the role of corticosteroids in the treatment of this disease is primarily ameliorative because they are ineffective in maintaining remission or healing mucosal lesions. Nearly half of the patients who ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1046/j.1365-2036.2001.01060.x

    authors： Rutgeerts PJ

    更新日期：2001-10-01 00:00:00

  • Serum gastrin levels during long-term omeprazole treatment.

    abstract：:Serum gastrin was determined in 33 patients during treatment with the proton pump inhibitor omeprazole. After 4 weeks of therapy, gastrin levels increased to a median of 55 pg/ml compared to 15 pg/ml prior to omeprazole (P less than 0.001). There was a close correlation (r = 0.939; P less than 0.001) between pre-treat...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.1990.tb00457.x

    authors： Koop H,Klein M,Arnold R

    更新日期：1990-04-01 00:00:00

  • Renal function and cardiovascular risk profile after conversion from ciclosporin to tacrolimus: prospective study in 80 liver transplant recipients.

    abstract：BACKGROUND:Increased risk of cardiovascular and cerebrovascular disease in liver transplant recipients results in particular from the side effects of calcineurin inhibitor-based immunosuppressive therapy. Several studies have demonstrated a more favourable outcome for patients receiving tacrolimus (TAC) as compared wit...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2009.04099.x

    authors： Beckebaum S,Klein C,Varghese J,Sotiropoulos GC,Saner F,Schmitz K,Gerken G,Paul A,Cicinnati VR

    更新日期：2009-10-15 00:00:00

  • Haemodynamic responses to 1.25 and 2 mg of terlipressin intravenously in man.

    abstract：:The systemic and hepatic haemodynamic effects following terlipressin (Glypressin) administration were studied. Bolus intravenous injections of 1.25 and 2 mg significantly decreased wedged hepatic vein pressure gradient by 29% and 31%, respectively. With each dose there was a small increase in mean arterial blood press...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.1988.tb00709.x

    authors： Freeman JG,Barton JR,Record CO

    更新日期：1988-08-01 00:00:00

  • Efficacy and safety of antiviral therapy in patients with Crohn's disease and chronic hepatitis C.

    abstract：BACKGROUND:Efficacy and safety of antiviral combination therapy in patients with Crohn's disease (CD) and chronic hepatitis C (CHC) is presently not established and consequently CHC is rarely treated in CD patients. AIM:To analyse the efficacy and tolerability of antiviral interferon/ribavirin therapy in patients with...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2008.03779.x

    authors： Scherzer TM,Staufer K,Novacek G,Steindl-Munda P,Schumacher S,Hofer H,Ferenci P,Vogelsang H

    更新日期：2008-09-15 00:00:00

  • Raised faecal calprotectin is associated with subsequent symptomatic relapse, in children and adolescents with inflammatory bowel disease in clinical remission.

    abstract：BACKGROUND:Reliable data on inflammatory biomarkers for predicting relapse of paediatric inflammatory bowel disease (IBD) are lacking. AIM:To investigate the predictive value of faecal calprotectin (FC) and CRP for symptomatic relapse in pediatric IBD in clinical remission. METHODS:In this cross-sectional cohort stud...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.13950

    authors： Diederen K,Hoekman DR,Leek A,Wolters VM,Hummel TZ,de Meij TG,Koot BG,Tabbers MM,Benninga MA,Kindermann A

    更新日期：2017-04-01 00:00:00

  • Efficacy of long-term therapy with low doses of omeprazole in the control of gastric acid secretion in Zollinger-Ellison syndrome patients.

    abstract：:Thirteen patients with Zollinger-Ellison syndrome were investigated: 8 without, and 5 with, previous gastric surgery. After 7-34 months of treatment with famotidine, 8 out of 13 patients were resistant to this drug. Omeprazole 60 mg/day was administered to these 8 patients; after one month, the dose was reduced to 40 ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.1993.tb00086.x

    authors： Corleto V,Annibale B,D'Ambra G,Saggioro A,Ferrua B,Cassetta MR,Delle Fave G

    更新日期：1993-04-01 00:00:00